For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Attruby represents a genuine breakthrough . These groundbreaking therapies stabilize the transthyretin protein, preventing its destructive build-up and lessening the severity of the condition . Patients are now reporting be